CEBPZ and acute myeloid leukemia: Although many centers worldwide have adopted the practice of adding GO to induction chemotherapy in patients with CBF-AML, the relatively modest OS in non-GO patients with favorable cytogenetics in the meta-analysis (55% at five years), along with the variability in IC regimens and inconsistent use of high-dose cytarabine consolidation, remain subjects of debate.